Acknowledgments

During the Substance Abuse Coverage Study, many individuals shared ideas and information with the study committee. The most important contributions in this respect were of two sorts: participation in two symposia organized by the committee in Washington, D.C., on June 1, 1988, and in Irvine, California, on October 4, 1988, and hosting of site visits by committee members and staff in six states during the intervening months.

The symposia gave the committee an opportunity to hear from and question closely a selection of knowledgeable individuals involved with drug treatment programs in a variety of roles such as clinical services, research, administration, third-party funding, and referral. These events gave the committee opportunities to hear not only individual presentations but also the participants' counterpoints to each other's and to the committee's tentative points of view. These exchanges breathed life into the committee's images of the treatment system, and committee members are grateful to all of the symposium participants for taking part in these important formative events.

Present at the Washington symposium were the following:

M. Douglas Anglin, Drug Abuse Research Group, University of California, Los Angeles

Patricia Armocida, Blue Cross/Blue Shield Association, Chicago, Illinois

John C. Ball, Addiction Research Center, Baltimore, Maryland

Lee Grutchfield, Human Resource Development, Continental Airlines, Houston, Texas

Norman Hoffmann, Chemical Addiction/Abuse Treatment Outcome Registry, The Ramsey Clinic, St. Paul, Minnesota

Don Jones, Consulting and Continuing Education Department, Hazelden Foundation, Minneapolis, Minnesota

Jill Klobucar, Human Affairs International, Arlington, Virginia

Richard J. Russo, New Jersey State Department of Health, Trenton

Steven Sharfstein, Sheppard and Enoch Pratt Hospital, Baltimore, Maryland

Bruce Vander Els, Milliman and Robertson, Radnor, Pennsylvania



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 317
Treating Drug Problems: Volume 2, Commissioned Papers on Historical, Institutional, and Economic Contexts of Drug Treatment Acknowledgments During the Substance Abuse Coverage Study, many individuals shared ideas and information with the study committee. The most important contributions in this respect were of two sorts: participation in two symposia organized by the committee in Washington, D.C., on June 1, 1988, and in Irvine, California, on October 4, 1988, and hosting of site visits by committee members and staff in six states during the intervening months. The symposia gave the committee an opportunity to hear from and question closely a selection of knowledgeable individuals involved with drug treatment programs in a variety of roles such as clinical services, research, administration, third-party funding, and referral. These events gave the committee opportunities to hear not only individual presentations but also the participants' counterpoints to each other's and to the committee's tentative points of view. These exchanges breathed life into the committee's images of the treatment system, and committee members are grateful to all of the symposium participants for taking part in these important formative events. Present at the Washington symposium were the following: M. Douglas Anglin, Drug Abuse Research Group, University of California, Los Angeles Patricia Armocida, Blue Cross/Blue Shield Association, Chicago, Illinois John C. Ball, Addiction Research Center, Baltimore, Maryland Lee Grutchfield, Human Resource Development, Continental Airlines, Houston, Texas Norman Hoffmann, Chemical Addiction/Abuse Treatment Outcome Registry, The Ramsey Clinic, St. Paul, Minnesota Don Jones, Consulting and Continuing Education Department, Hazelden Foundation, Minneapolis, Minnesota Jill Klobucar, Human Affairs International, Arlington, Virginia Richard J. Russo, New Jersey State Department of Health, Trenton Steven Sharfstein, Sheppard and Enoch Pratt Hospital, Baltimore, Maryland Bruce Vander Els, Milliman and Robertson, Radnor, Pennsylvania

OCR for page 317
Treating Drug Problems: Volume 2, Commissioned Papers on Historical, Institutional, and Economic Contexts of Drug Treatment Participants in the Irvine symposium were: M. Douglas Anglin, Drug Abuse Research Group, University of California, Los Angeles Gary Atkins, Employee Assistance Programs, Lockheed Missile and Space, Sunnyvale, California Sherry Conrad, Department of Alcohol and Drug Programs, State of California, Sacramento Michael Q. Ford, National Association of Addiction Treatment Providers, Irvine, California Uwe Gunnerson, Azure Acres Chemical Dependency Rehabilitation Center, Sebastopol, California Y-Ing Hser, Drug Abuse Research Group, University of California, Los Angeles Ed Liebson, Blue Cross of California, Oakland Anthony Radcliffe, Kaiser-Permanente Medical Center, Fontana, California Galen Rogers, Preferred Management, San Diego, California William Smith, Phoenix House, Santa Anna, California Irma Strantz, Department of Health Services, County of Los Angeles, California Susan Zepeda, Orange County Health Services Administration, Santa Anna, California The committee's hosts during site visits to cities across the country offered a degree of cooperation, hospitality, and candor in response to the committee's questions that made a deep and lasting impression. The hosts received assurance that no comments or observations would be attributed to specific individuals or organizations and that individual anonymity would be full preserved. Many of those visited indicated that such assurances were not a precondition for their cooperation; nevertheless, these guarantees have been observed in the report, and the committee feels that it is important to uphold them here. Therefore, names of the many individual hosts in whose debt the study remains are not included here. The committee wishes, however, at least to signal the extent of their contributions by expressing its thanks to each of the following organizations for permitting access to their staff and facilities: AIDS Outreach Project, Portland, Oregon Allegheny County Mental Health, Mental Retardation, and Drug Abuse Program, Pittsburgh, Pennsylvania Bank of America, San Francisco, California Bay Area Treatment Services, Berkeley, California Beth Israel Medical Center, New York, New York

OCR for page 317
Treating Drug Problems: Volume 2, Commissioned Papers on Historical, Institutional, and Economic Contexts of Drug Treatment The City of New York Office of Municipal Labor Relations Comprehensive Care Corporation, Irvine, California Comprehensive Options for Drug Abusers, Portland, Oregon Cornerstone Correctional Treatment Program, Salem, Oregon Daytop Village, New York, New York Gateway Program, St. Louis, Missouri Hooper Memorial Center, Central City Concern, Portland, Oregon Hyland Center, St. Anthony Hospital, St. Louis, Missouri Ielase Institute of Forensic Psychiatry, Pittsburgh, Pennsylvania International Association of Machinists and Aerospace Workers, District 100, Miami, Florida ITT Corporation, New York, New York Jewish Hospital Chemical Dependency Program, Washington University at St. Louis, Missouri Martin Luther King/Charles A. Drew Medical Center, Los Angeles, California Metro Dade County Office of Rehabilitative Services, Miami, Florida Metro Dade County Office of Substance Abuse Control, Miami, Florida Missouri Department of Mental Health, Division of Alcohol and Drugs, St. Louis Multnomah County Alcohol and Drug Program, Portland, Oregon Narcotic and Drug Research, Inc., New York, New York Narcotics Addiction Services Council, St. Louis, Missouri New York State Division of Substance Abuse Services, Albany PBA, Inc., The Second Step, Pittsburgh, Pennsylvania Project for Community Recovery, Portland, Oregon Project Rediscovery, Pittsburgh, Pennsylvania Providence Medical Center, Portland, Oregon Office of the State Attorney, Eleventh Judicial Circuit of Florida, Miami Outside-In, Portland, Oregon Regional Drug Initiative, Portland, Oregon St. Francis Hospital, Pittsburgh, Pennsylvania Spectrum Programs, Miami, Florida Southwestern Bell, St. Louis, Missouri State of Oregon Office of Alcohol and Drug Abuse Programs, Salem TASC of Oregon, Portland Up Front Drug Information Center, Miami, Florida Walden House, San Francisco, California Watts Health Foundation, Los Angeles, California Western Health Services, Portland, Oregon A final thanks is due to individuals who responded to the committee's questions in writing or with substantive materials that might not otherwise

OCR for page 317
Treating Drug Problems: Volume 2, Commissioned Papers on Historical, Institutional, and Economic Contexts of Drug Treatment have become known to the committee. These correspondents include Leslie Acoca, Novato, California; Karl Bernstein, Silver Spring, Maryland; Sheila Blume, Amityville, New York; Frank R. Burger, Nashville, Tennessee; Frank N. Coogan, Milwaukee, Wisconsin; Thomas J. Doherty, Washington, D.C.; Julie Donalson, Sacramento, California; P. Joseph Frawley, Santa Barbara, California; Cherry Lowman, New York, New York; Judith Ovisher, Arlington, Virginia; Max A. Schneider, Orange, California; James W. Smith, Santa Barbara, California; Jack R. Slaberg, Nashville, Tennessee; and Emanuel M. Steindler, New York, New York.